Ken Griffin Aadi Bioscience, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,800 shares of AADI stock, worth $52,836. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,800
Previous 9,400
153.19%
Holding current value
$52,836
Previous $13,000
276.92%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding AADI
# of Institutions
55Shares Held
12.6MCall Options Held
23.8KPut Options Held
0-
Avoro Capital Advisors LLC New York, NY2.85MShares$6.33 Million0.09% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2MShares$4.44 Million2.42% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$4.11 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.85MShares$4.1 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$1.7 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $46.7M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...